Psychoplastogens: What do we know about them?
Jyothsna Kuralla, Harsh Chaturvedi
International Journal of Pharmacology and Clinical Research May 1, 2026 DOI: 10.33545/26647613.2026.v8.i5a.255 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Ketamine Psilocybin Scopolamine LSD DMT Ibogaine MDMA |
| Key findings | The authors argue that psychoplastogens such as ketamine, psilocybin, scopolamine, LSD, DMT, ibogaine, and MDMA promote neuroplasticity through glutamatergic and serotonergic pathways and show rapid antidepressant effects, often within hours of a single dose and sustained for days or weeks, particularly in treatment-resistant depression. They contend these compounds signal a shift from the monoamine hypothesis toward circuit-based psychiatry, while cautioning that side effects, psychological risks, and misconceptions require regulatory frameworks, long-term safety data, and informed patient engagement. |
Abstract
Major depressive disorder (MDD) remains a global health burden, with over 60% of patients failing to respond adequately to current treatments. Treatment-resistant depression (TRD), a form of MDD, highlights the urgent need for mechanistically novel antidepressants. Psychoplastogens—a class of fast-acting compounds that promote neuroplasticity—are emerging as promising alternatives to conventional therapies. This review explores the neurobiological mechanisms, therapeutic efficacy, and safety profiles of leading psychoplastogens including ketamine, psilocybin, scopolamine, LSD, DMT, ibogaine, and MDMA. These compounds act primarily through glutamatergic and serotonergic pathways, rapidly enhancing synaptogenesis and dendritic remodeling in prefrontal circuits implicated in mood regulation. Ketamine, an NMDA antagonist, is a well-validated psychoplastogen with rapid effects in TRD, while psilocybin and LSD act as 5-HT2A agonists that alter network-level brain connectivity. Scopolamine’s antimuscarinic effects and MDMA’s prosocial properties further broaden the psychoplastogen category. Clinical and preclinical data support their rapid antidepressant effects, often observed within hours of a single dose and sustained for days or weeks. However, concerns regarding side effects, psychological risks, and media-fueled misconceptions require caution. This analysis underscores the therapeutic relevance of psychoplastogens in addressing unmet needs in depression treatment. Their ability to reshape dysfunctional brain circuits presents a paradigm shift away from the monoamine hypothesis toward circuit-based psychiatry. Still, their integration into clinical practice demands robust regulatory frameworks, long-term safety data, and informed patient engagement. In conclusion, psychoplastogens offer a promising new direction for individualized and rapid relief of depressive symptoms, especially in TRD, but must be applied judiciously within evidence-based therapeutic settings.